TY - GEN
T1 - Total phenolic, UPLC-QTOF-MS analysis and antidepressant-like effect in the mice forced swim test of Jamu Neuropathic Pain Reducer
AU - Hanifah, Aisyah
AU - Tristantini, Dewi
N1 - Publisher Copyright:
© 2019 Author(s).
PY - 2019/12/10
Y1 - 2019/12/10
N2 - Neuropathic (nerve) pain is caused by damage, dysfunction or injury of nerves it will affect patient's quality of life because of chronicity and intensity. The pharmaceutical drug commonly used to treat neuropathic pain is antidepressants. However, Anti-depressant drug has dangerous side effects if consumed continuously. Herbs treatments use throughout the world for the treatment of neuropathic pain. Jamu Neuropathic Pain Reducer, which consists of aqueous multi herbs extract of nutmeg seed (Myristica fragrans), clove bud (Syzygium aromaticum) and red ginger rhizome (Zingiber officinale var rubrum) was extracted with variation temperature (60, 80, 100). This study aimed to figure out the total phenolic content (TPC) in the Jamu Neuropathic Pain Reducer used the Folin-Ciocalteu method. The highest TPC (33.58 ± 1.473mg GAE/g herb) happened at temperature 80. UPLC-QTOF-MS applied to identify the major bioactive compound in Jamu Neuropathic Pain Reducer extract used temperature extraction 80, analysis revealed the presence of compounds such as adenine, chlorogenic acid, miquelianin, quercitrin, 6-gingerol, myristicin, and eugenol. Jamu Neuropathic Pain Reducer reduced the immobility duration compared with the control negative (distilled water) (p < 0.001). The reductions of the immobility time were 8.3%, 36.4% and 30.1% for dosage 16.25 mL/kg, 32.5 mL/kg and 65 mL/kg, therefore, Jamu Neuropathic Pain Reducer had the potential to be an alternative as herbal medicine for neuropathic pain that less expensive and has minimum side effect.
AB - Neuropathic (nerve) pain is caused by damage, dysfunction or injury of nerves it will affect patient's quality of life because of chronicity and intensity. The pharmaceutical drug commonly used to treat neuropathic pain is antidepressants. However, Anti-depressant drug has dangerous side effects if consumed continuously. Herbs treatments use throughout the world for the treatment of neuropathic pain. Jamu Neuropathic Pain Reducer, which consists of aqueous multi herbs extract of nutmeg seed (Myristica fragrans), clove bud (Syzygium aromaticum) and red ginger rhizome (Zingiber officinale var rubrum) was extracted with variation temperature (60, 80, 100). This study aimed to figure out the total phenolic content (TPC) in the Jamu Neuropathic Pain Reducer used the Folin-Ciocalteu method. The highest TPC (33.58 ± 1.473mg GAE/g herb) happened at temperature 80. UPLC-QTOF-MS applied to identify the major bioactive compound in Jamu Neuropathic Pain Reducer extract used temperature extraction 80, analysis revealed the presence of compounds such as adenine, chlorogenic acid, miquelianin, quercitrin, 6-gingerol, myristicin, and eugenol. Jamu Neuropathic Pain Reducer reduced the immobility duration compared with the control negative (distilled water) (p < 0.001). The reductions of the immobility time were 8.3%, 36.4% and 30.1% for dosage 16.25 mL/kg, 32.5 mL/kg and 65 mL/kg, therefore, Jamu Neuropathic Pain Reducer had the potential to be an alternative as herbal medicine for neuropathic pain that less expensive and has minimum side effect.
KW - antidepressant activity
KW - herbs
KW - neuropathic pain
KW - UPLC-QTOF-MS-Analysis
UR - http://www.scopus.com/inward/record.url?scp=85076796246&partnerID=8YFLogxK
U2 - 10.1063/1.5139347
DO - 10.1063/1.5139347
M3 - Conference contribution
AN - SCOPUS:85076796246
T3 - AIP Conference Proceedings
BT - 4th Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, Health, and Medical Devices
A2 - Lischer, Kenny
A2 - Abuzairi, Tomy
A2 - Rahman, Siti Fauziyah
A2 - Gozan, Misri
PB - American Institute of Physics Inc.
T2 - 4th International Symposium of Biomedical Engineering�s Recent Progress in Biomaterials, Drugs Development, Health, and Medical Devices, ISBE 2019
Y2 - 22 July 2019 through 24 July 2019
ER -